OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
Guo–Ming Shi, Xiaoyong Huang, Dong Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 80
Guo–Ming Shi, Xiaoyong Huang, Dong Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 80
Showing 1-25 of 80 citing articles:
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
Jia‐Cheng Lu, Lei‐Lei Wu, Yining Sun, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Jia‐Cheng Lu, Lei‐Lei Wu, Yining Sun, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
Xu Yang, Baofeng Lian, Nan Zhang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Xu Yang, Baofeng Lian, Nan Zhang, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
Ziting Peng, Jianhui Dong, Shuyao Tang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Ziting Peng, Jianhui Dong, Shuyao Tang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma
Rongce Zhao, Jing Zhou, Zhaoxia Miao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Rongce Zhao, Jing Zhou, Zhaoxia Miao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
Huizi Sha, Fan Tong, Jiayao Ni, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Huizi Sha, Fan Tong, Jiayao Ni, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Emerging Therapies in Management of Cholangiocarcinoma
Jessica Speckart, Veronica Rasmusen, Zohray Talib, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 613-613
Open Access | Times Cited: 6
Jessica Speckart, Veronica Rasmusen, Zohray Talib, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 613-613
Open Access | Times Cited: 6
Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma
YeXing Huang, ZeFeng Du, Anna Kan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
YeXing Huang, ZeFeng Du, Anna Kan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Seung Bae Yoon, Sang Myung Woo, Jung Won Chun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 5
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 5
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer
Ting Zhang, Chengpei Zhu, Nan Zhang, et al.
International Immunopharmacology (2024) Vol. 129, pp. 111642-111642
Closed Access | Times Cited: 4
Ting Zhang, Chengpei Zhu, Nan Zhang, et al.
International Immunopharmacology (2024) Vol. 129, pp. 111642-111642
Closed Access | Times Cited: 4
Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case
Hewei Zhang, Haibo Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Hewei Zhang, Haibo Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Aung Naing, Amit Mahipal, Milind Javle, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 1, pp. 71-81
Open Access
Aung Naing, Amit Mahipal, Milind Javle, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 1, pp. 71-81
Open Access
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer
Sirui Tan, Mingyang Feng, Nan Zhou, et al.
Cancer (2025) Vol. 131, Iss. 3
Closed Access
Sirui Tan, Mingyang Feng, Nan Zhou, et al.
Cancer (2025) Vol. 131, Iss. 3
Closed Access
Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
Hao Su, Xiao Shang, Hongruo Liu, et al.
International Journal of Women s Health (2025) Vol. Volume 17, pp. 325-333
Open Access
Hao Su, Xiao Shang, Hongruo Liu, et al.
International Journal of Women s Health (2025) Vol. Volume 17, pp. 325-333
Open Access
Nanomaterials for liver cancer targeting: research progress and future prospects
Jiahong Xu, Yefu Liu
Frontiers in Immunology (2025) Vol. 16
Open Access
Jiahong Xu, Yefu Liu
Frontiers in Immunology (2025) Vol. 16
Open Access
Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma
Miao Li, Tong Li, Rongxin Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Miao Li, Tong Li, Rongxin Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation
Ning Zhang, Linmao Sun, Shuo Zhou, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Ning Zhang, Linmao Sun, Shuo Zhou, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy
Naoshi Nishida
Cancers (2025) Vol. 17, Iss. 7, pp. 1243-1243
Open Access
Naoshi Nishida
Cancers (2025) Vol. 17, Iss. 7, pp. 1243-1243
Open Access
Application of machine learning models to explore prognosis and cause of death in advanced intrahepatic cholangiocarcinoma patients undergoing chemotherapy
Qin Zeng, Xin Wang, Jun Liu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Qin Zeng, Xin Wang, Jun Liu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges
Jun-Jie Liu, Mi Zhou, Tong Yuan, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 15
Closed Access
Jun-Jie Liu, Mi Zhou, Tong Yuan, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 15
Closed Access
Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner
Wangjie Jiang, Xiaoli Shi, Lizhu Sun, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 14, pp. 4571-4587
Open Access | Times Cited: 10
Wangjie Jiang, Xiaoli Shi, Lizhu Sun, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 14, pp. 4571-4587
Open Access | Times Cited: 10
Effect of different PD ‐1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma
Zhengqing Lei, Weihu Ma, Anfeng Si, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 6, pp. 611-622
Closed Access | Times Cited: 9
Zhengqing Lei, Weihu Ma, Anfeng Si, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 6, pp. 611-622
Closed Access | Times Cited: 9
